Bioengineered Liver Support Shows Promise in Early Trials for Acute Liver Failure

A biotech company claims its lab-grown liver cells could revolutionize care for patients with life-threatening liver failure.

United Therapeutics reported positive Phase 1 trial results for its bioengineered liver support system in treating acute liver failure. The trial involved 12 patients, all of whom survived the treatment period (98% survival rate, with one patient lost to follow-up). Dr. Martine Rothblatt, CEO of United Therapeutics, said:

"The results demonstrate that our liver support system can safely and effectively bridge patients to recovery or transplant."

The system uses bioengineered human liver cells to perform metabolic functions while the patient's liver recovers.

No serious adverse events were reported during the trial. However, the study is limited to Phase 1, which primarily assesses safety and feasibility rather than long-term efficacy. Experts caution that more research is needed before changing clinical practice.

⚠️ LEGAL DISCLAIMER: It is for informational purposes only. It never substitutes for professional medical advice, diagnosis, or treatment. Always consult your doctor regarding any questions about your health.